Clinical Trials Browser

Phase 1/2 × Immunotherapy × 90 days × Clear all

NCT07595172 2026-05-19

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular